Skip to main content

Table 2 Outcome of ovarian stimulation

From: GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

  Cabergoline group (n = 118) Antagonist rescue combined with cabergoline group (n = 118) P value
Duration of HP-uFSH Stimulation (days) 9.92 ± 0.85 10.08 ± 0.68 0.129
Total HP-uFSH ampoules (75U) 29.88 ± 6.8 27.87 ± 5.58 0.014
Estradiol level on the HCG day (pg/ml) 5501 ± 1122 2811 ± 399 <0.001
No. of retrieved oocytes 19.09 ± 4.01 18.85 ± 4.37 0.651
No. of metaphase II oocytes 17.02 ± 3.8 16.97 ± 3.94 0.933
No. of fertilized oocytes 13.69 ± 3.32 13.42 ± 3.08 0.523
Fertilization rate 1584/2003(79.08 %) 1561/1940(80.46 %) 0.28
No. of high quality embryos 4.02 ± 1.28 3.84 ± 1.31 0.295
No. of embryos transferred 2.32 ± 0.47 2.26 ± 0.44 0.303
Cycles cancelled 4/118(3.39 %) 0/118(0 %) 0.122
Moderate or severe OHSS 16/118(13.56 %) 6/118(5.08 %) 0.025
Moderate OHSS 12/118(10.17 %) 6/118(5.08 %) 0.141
Severe OHSS 4/118(3.39 %) 0/118(0 %) 0.122
Early onset OHSS 12/118(10.17 %) 5/118(4.24 %) 0.078
Late onset OHSS 4/118(3.39 %) 1/118(0.85 %) 0.37
  1. OHSS ovarian hyperstimulation syndrome
  2. Values are expressed as mean ± SD or n/n(%)